FDA Commissioner Martin Makary recently highlighted the role of CGMs in preventing chronic conditions, questioning why they are only available on prescription. Could there be any benefit to the diabetes community of a policy change?
New medtech startup, Luna Health, based in the US, have raised $23.6 million to advance a patch pump designed specifically for overnight use only.
News that Abbott have agreed to collaborate with 4 pump providers for hybrid closed loop with their future combined glucose - ketone sensor.
News that Eversense 365 has been named Best New Technology Solution for Diabetes Management in the 2025.
FDA approval of Simplera Sync sensor paired with MiniMed™ 780G insulin pump.
News that approval from the FDA of the Dexcom G7 15 day CGM in the US, with a grace period of 12 hours, makes this the longest lasting CGM.
Latest news from key diabetes conference covering the latest in medtech, treatments, research and 'cures'.
News that the National Institutes of Health halted the grant for the Diabetes Prevention Program last week, though no reason has been given.
Dexcom's financial filings reveal a warning letter from the FDA regarding processing in 2 of its manufacturing plants.
Abbott announce that FreeStyle Libre 3 sensors will be phased out in the UK by the end of 2025 and users will need to move to FreeStyle Libre 3 Plus.
A new CGM launches this February in the UK.
